What Transformation Has the Immuno-Oncology Drugs Market Undergone?
The immuno-oncology drugs market has seen considerable growth due to a variety of factors.
• The market size for immuno-oncology drugs has experienced significant expansion in the past few years. There is a projected growth from $94.16 billion in 2024 to $106.92 billion in 2025, representing a compound annual growth rate (CAGR) of 13.6%.
Factors contributing to the growth during the historical period include a surge in cancer diagnoses, robust economic development in emerging markets, escalated health care investing, and a surge in pharmaceutical research and development spending.
What Is The Forecast For The Immuno-Oncology Drugs Market By 2029?
The immuno-oncology drugs market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the immuno-oncology drugs market to undergo substantial growth in the coming years, with projections placing its value at $153.16 billion in 2029 at a compounded annual growth rate (CAGR) of 9.4%.
The anticipated growth in the forecast period is credited to the escalating investment in immuno-oncology, the increasing attention on immunotherapy drugs for cancer treatment, and product advancements. Noteworthy trends for this period will be the investment in the creation of personalized oncology drugs aimed at treating specific patients, the emphasis on the cultivation of next-generation biologics and the development of antibody-drug conjugates. Additionally, investment in AI solutions will aim to decrease R&D costs and save development time, with a focus on immune-oncology combination therapies to stimulate innovation and build category leadership, along with the implementation of car-t therapies to fuel more innovations and establish category dominance.
What Are the Critical Driver Fuelling the Immuno-Oncology Drugs Market's Growth?
The escalating prevalence of cancer worldwide is expected to stimulate the expansion of the immuno-oncology drugs market. For example, the American Cancer Society projected in January 2022 that there would be an estimated 1.9 million fresh cancer cases and 609,360 cancer-related fatalities in the US alone, equating to about 1,670 deaths daily. The four cancers that contribute 43% of all new diagnoses globally are lung, prostate, bowel, and female breast cancer. Given this worldwide surge in cancer cases, the demand for immuno-oncology drugs is predicted to increase in the following years.
How Is The Globa Immuno-Oncology Drugs Market Divided Into Key Segments?
The immuno-oncology drugs market covered in this report is segmented –
1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others
Subsegments:
1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors
3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies
4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Others: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies
Pre-Book The Immuno-Oncology Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Immuno-Oncology Drugs Market?
Leading entities in the immuno-oncology drugs market are forming partnerships to create and market a new checkpoint antibody, which will improve the efficiency of cancer treatments. Such strategic alliances encourage innovation by facilitating the sharing of knowledge across different disciplines, thereby accelerating the invention of combination therapies, customized treatments, and new drug delivery methods. For example, in March 2023, BioNTech SE, a company located in Germany, collaborated with OncoC4 Inc, a pharmaceutical company from the U.S., to jointly develop and market a checkpoint antibody, particularly the anti-CTLA-4 monoclonal antibody candidate named ONC-392. The objective behind this collaboration is to improve cancer treatment methods for a variety of solid tumor indications.
Who Are the Key Players in the Immuno-Oncology Drugs Market?
Major companies operating in the immuno-oncology drugs market include:
• F. Hoffmann-La Roche Ltd.
• Merck & Co.
• Bristol-Myers Squibb Company
• Amgen Inc
• Johnson & Johnson
• AstraZeneca Plc
• Eli Lilly and Company
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.
• Arlak Biotech
• Apikos Pharma
• Kolaz biotech
• CStone Pharma
• CARsgen Therapeutics
• JW Therapeutics
• BeiGene
• Takeda Pharmaceuticals
• Astellas Pharma Inc
• Otsuka Pharmaceutical Co. Ltd
• Legend Biotech Co
• Zai Lab
• Daiichi Pharmaceutical and Sankyo
• AQVIDA GmbH
• Baxter International Inc.
• GlaxoSmithKline plc
• Affimed Therapeutics
• Autolus Therapeutics
• Cellectis
• Celyad
• GammaDelta Therapeutics
• Immunocore
• European Medical Center (EMC)
• Yauza Medical Center
• Celon Pharma
• Veropharm
• Biocad
• Selvita
• OncoArendi Therapeutics Mabion
• Fate Therapeutics
• Forty-Seven
• Arcus Biosciences
• Gritstone Oncology
• Rakuten Medical
• Rubius Therapeutics
• Allogene Therapeutics
• Celgene Corporation
• Bayer AG. Incyte Corporation
• Recepta Biopharma
• CSC Pharmaceuticals International
• Blanver EN
• Sandoz Brazil
• Life Pharma
• Julphar
• NewBridge Pharmaceuticals
• Eurolab
What are the Regional Insights into the Immuno-Oncology Drugs Market?
North America was the largest region in the immuno-oncology drugs market in 2024. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
